NYSE:SNN

Smith & Nephew (SNN) Stock Forecast, Price & News

$24.06

-0.71 (-2.87%)

(As of 10/2/2023 ET)

Compare

Today's Range: $23.98
▼
$24.29
50-Day Range: $24.33
▼
$31.29
52-Week Range: $21.85
▼
$33.08

Volume: 759,203 shs
Average Volume: 853,306 shs
Market Capitalization: $10.50 billion

P/E Ratio: N/A
Dividend Yield: 3.74%
Price Target: N/A

Smith & Nephew MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.20% of Float Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.92
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 9.20%
From $1.74 to $1.90 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

408th out of 969 stocks

Surgical Appliances & Supplies Industry

10th out of 20 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Smith & Nephew.

5.0

Short Interest

Percentage of Shares Shorted
0.20% of the float of Smith & Nephew has been sold short.
Short Interest Ratio / Days to Cover
Smith & Nephew has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Smith & Nephew has recently decreased by 49.54%, indicating that investor sentiment is improving significantly.

2.5

Dividend Strength

Dividend Leadership
Smith & Nephew is a leading dividend payer. It pays a dividend yield of 3.65%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Smith & Nephew does not have a long track record of dividend growth.
Dividend Sustainability
Based on earnings estimates, Smith & Nephew will have a dividend payout ratio of 47.37% next year. This indicates that Smith & Nephew will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SNN.

3.3

News and Social Media Coverage

News Sentiment
Smith & Nephew has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Smith & Nephew this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for SNN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
4 people have added Smith & Nephew to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Smith & Nephew insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.00% of the stock of Smith & Nephew is held by insiders.
Percentage Held by Institutions
Only 8.65% of the stock of Smith & Nephew is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Smith & Nephew are expected to grow by 9.20% in the coming year, from $1.74 to $1.90 per share.
Price to Earnings Growth Ratio
Smith & Nephew has a PEG Ratio of 1.26. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Smith & Nephew has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Smith & Nephew (NYSE:SNN) Stock

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products, including instruments, technologies, and implants to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

SNN Price History

30 days | 90 days | 365 days | Advanced Chart

SNN Stock News Headlines

September 27, 2023 | money.usnews.com

Smith & Nephew plc - ADR

September 22, 2023 | americanbankingnews.com

Smith & Nephew (NYSE:SNN) Rating Increased to Strong-Buy at StockNews.com

October 2, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

August 4, 2023 | seekingalpha.com

Smith & Nephew plc 2023 Q2 - Results - Earnings Call Presentation

August 3, 2023 | msn.com

Smith & Nephew ups growth expectations after strong first half of 2023

August 3, 2023 | seekingalpha.com

Smith & Nephew Non-GAAP EPS of $0.35, revenue of $2.73B

August 3, 2023 | benzinga.com

Smith & Nephew Raises Revenue Growth Outlook After Strong 1H Performance, Sports Medicine and Wound Management Show Strength

June 17, 2023 | finance.yahoo.com

Boeing, CyberArk Lead 5 Stocks Near Buy Points

October 2, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

June 12, 2023 | msn.com

Smith+Nephew gets FDA clearance for AETOS shoulder implant system

June 12, 2023 | finance.yahoo.com

Smith+Nephew announces 510(k) clearance of its AETOS™ Shoulder System for anatomic and reverse shoulder replacement

May 4, 2023 | marketwatch.com

Smith & Nephew falls Thursday, still outperforms market

April 27, 2023 | msn.com

Smith & Nephew reports strong first quarter growth with £44m sales uplift

April 14, 2023 | forbes.com

Smith & Nephew (SNN) Buy Write Still Good To Go

April 13, 2023 | forbes.com

Smith & Nephew Buy Write

March 31, 2023 | thestreet.com

Smith & Nephew Stock To Go Ex-dividend Tomorrow (SNN)

March 26, 2023 | finance.yahoo.com

Here's Why We're Wary Of Buying Smith & Nephew's (LON:SN.) For Its Upcoming Dividend

March 23, 2023 | finance.yahoo.com

New evidence demonstrates Smith+Nephew's COBLATION™ Technology can accelerate patient recovery with fewer complications compared with total tonsillectomy techniques

March 14, 2023 | marketwatch.com

Smith & Nephew rises Tuesday, outperforms market

March 13, 2023 | marketwatch.com

Smith & Nephew outperforms market despite losses on the day

March 9, 2023 | finance.yahoo.com

Smith & Nephew (SNN) Simplifies ACL Surgery With New Offers

March 8, 2023 | finance.yahoo.com

Smith+Nephew to highlight procedural innovations in Sports Medicine during AAOS 2023 Annual Meeting

February 24, 2023 | seekingalpha.com

Smith & Nephew: Flat FY22 Growth, Now An Execution Story

February 24, 2023 | finance.yahoo.com

Investors’ Chronicle: Antofagasta, Hays, Smith & Nephew

February 23, 2023 | finance.yahoo.com

What Makes Smith & Nephew (SNN) a New Buy Stock

February 21, 2023 | msn.com

Smith & Nephew profits shrink amid major fall in Bioventus holding

February 17, 2023 | msn.com

Smith & Nephew reveals Rupert Soames will become next chairman

See More Headlines

Receive SNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter.

SNN Company Calendar

Last Earnings: 11/17/2014
Today: 10/02/2023
Ex-Dividend for 11/1 Dividend: 10/05/2023
Dividend Payable: 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Surgical appliances & supplies
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:SNN
CUSIP: N/A
CIK: 845982
Web: www.smith-nephew.com
Phone: 441923477100
Fax: 44-20-7930-3353
Employees: 19,012
Year Founded: 1856

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: 13.82
P/E Growth: 1.26
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.50
Current Ratio: 2.19
Quick Ratio: 0.83

Sales & Book Value

Annual Sales: $5.22 billion
Price / Sales: 2.01
Cash Flow: $2.97 per share
Price / Cash Flow: 8.11
Book Value: $12.08 per share
Price / Book: 1.99

Miscellaneous

Outstanding Shares: 436,700,000
Free Float: 432,330,000
Market Cap: $10.50 billion
Optionable: Optionable
Beta: 0.66

Social Links

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Deepak S. Nath Ph.D. (Age 51)
CEO & Director
Comp: $5.96M

Ms. Anne-Francoise Nesmes (Age 51)
CFO & Exec. Director
Comp: $1.35M

Mr. Paul Connolly (Age 55)
Pres of Global Operations

Mr. Andrew Swift
VP of Investor Relations

Ms. Helen Barraclough (Age 43)
Group Gen. Counsel & Company Sec.

Ms. Alison Parkes (Age 50)
Chief Compliance Officer & Compliance APAC

Mr. Joe Metzger
Sr. VP of Marketing Services & Communications

Mr. Philip G. Cowdy (Age 56)
Chief Corp. Devel. & Corp. Affairs Officer

Ms. Elga Lohler (Age 55)
Chief HR Officer

Mr. Bradley Cannon (Age 55)
Pres of Global Orthopaedics

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SNN Stock - Frequently Asked Questions

Should I buy or sell Smith & Nephew stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SNN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNN, but not buy additional shares or sell existing shares.
View SNN analyst ratings or view top-rated stocks.
How have SNN shares performed in 2023?: Smith & Nephew's stock was trading at $26.89 at the beginning of the year. Since then, SNN stock has decreased by 10.6% and is now trading at $24.05.
View the best growth stocks for 2023 here.
Are investors shorting Smith & Nephew?: Smith & Nephew saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 883,000 shares, a decline of 49.5% from the August 31st total of 1,750,000 shares. Based on an average daily volume of 809,300 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.2% of the shares of the stock are sold short.
View Smith & Nephew's Short Interest.
How were Smith & Nephew's earnings last quarter?: Smith & Nephew plc (NYSE:SNN) announced its quarterly earnings data on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.39 by $0.59.
How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?: Smith & Nephew announced a semi-annual dividend on Thursday, August 3rd. Investors of record on Friday, October 6th will be paid a dividend of $0.462 per share on Wednesday, November 1st. This represents a yield of 2.6%. The ex-dividend date of this dividend is Thursday, October 5th.
Read our dividend analysis for SNN.
Is Smith & Nephew a good dividend stock?: Smith & Nephew (NYSE:SNN) pays an annual dividend of $0.90 per share and currently has a dividend yield of 3.65%.
Read our dividend analysis for SNN.

What other stocks do shareholders of Smith & Nephew own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Smith & Nephew investors own include Smith & Nephew (SN), RPM International (RPM), Gilead Sciences (GILD), AbbVie (ABBV), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Abbott Laboratories (ABT), Alexion Pharmaceuticals (ALXN) and Amgen (AMGN).
What is Smith & Nephew's stock symbol?: Smith & Nephew trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNN."
How do I buy shares of Smith & Nephew?: Shares of SNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Smith & Nephew's stock price today?: One share of SNN stock can currently be purchased for approximately $24.05.
How much money does Smith & Nephew make?: Smith & Nephew (NYSE:SNN) has a market capitalization of $10.50 billion and generates $5.22 billion in revenue each year.
How many employees does Smith & Nephew have?: The company employs 19,012 workers across the globe.
How can I contact Smith & Nephew?: Smith & Nephew's mailing address is BUILDING 5 CROXLEY PARK HATTERS LANE, WATFORD X0, WD18 8YE. The official website for the company is www.smith-nephew.com. The medical equipment provider can be reached via phone at 441923477100, via email at andrew.swift@smith-nephew.com, or via fax at 44-20-7930-3353.

This page (NYSE:SNN) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial